MET and neoplasm: In the LU5381 models with the IHC 3+ and MET exon14 skipping mutation, ABN401 suppressed tumor growth with a TGI of 63.09% and 75.47% at doses of 10 and 30 mg/kg, respectively, as shown in Figure 3G and Table 1.